Hoppe is an international expert in particle therapy and helps educates physicians worldwide via lectures and published review articles and chapters. Specifically, his work has been patient focused on improvements in quality of life and reducing the risk of side effects from radiation.ĭr. His research activities have focused on investigating the role of particle therapy in improving outcomes in cancer patients. Hoppe participates in the multi-disciplinary approach to the management of patients with cancer, which includes weekly tumor conferences, where new patient cases are presented and discussed amongst specialty providers including oncologists, radiation oncologists, surgeons, radiologists. His interest is to provide outstanding patient care, conduct research to improve patient outcomes, and help train the next generation of radiation oncologists.ĭr. He specializes in the management of patients with lymphoma, lung cancer, thymic cancer, prostate cancer, and GI malignancies. As noted in the American Radium Society appropriate use criteria guidelines,32 a reasonable approach might be to devise a radiation plan for 50.0 to 50.4 Gy before the start of nCRT, with the plan to stop at 40.0 to 41.4 Gy once an operable patients wish to proceed with surgery is assured.

Bradford Hoppe, M.D., MPH, is a Professor of Radiation Oncology and the Medical Director of Particle Therapy. One American Radium Society (ARS) appropriate-use paper is specific to the question of unilateral RT for tonsil cancer, summarizing major studies and ending with a determination of consensus not reached regarding the use of unilateral RT in patients with nodal stage N2b.

American radium society grant